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Core evidence proof of concept summary for panitumumab in metastatic colorectal cancer

  **Outcome measure**    **Emerging evidence**
  ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Efficacy               Potential to use as monotherapy (at a dose of 6 mg/kg every 3 weeks) or in combination with chemotherapy (at a dose of 2.5 mg/kg once per week); stable disease achieved in up to 46% of patients, and progression-free survival of 2--10.9 months
  Response rates         Evidence of activity with a response rate between 10% and 36%
  Biomarker expression   Even in studies where immunohistochemistry expression of EGFR was required, it does not correlate with objective response
  Tolerability           Good toxicity profile; no maximum tolerated dose has been reported, and no differences in pharmacokinetic parameters between the once weekly, every 2 weeks, and every 3 weeks dosage schedules

EGFR, epidermal growth factor receptor.

Scope, aims, and objectives
===========================

Colorectal cancer is the fourth most common malignant disease ([@b18-ce-2-081]; [@b23-ce-2-081]) and the second leading cause of cancer death in the USA ([@b19-ce-2-081]; [@b23-ce-2-081]). Even though different therapeutic strategies with new drugs have doubled the median overall survival (OS) of metastatic colorectal cancer patients up to 21.5 months, it remains less than 2 years. Active salvage options are clearly needed for this disease.

Panitumumab (ABX-EGF) is the first fully human monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) to be investigated in colorectal cancer. The objective of this review is to evaluate the potential role of panitumumab in metastatic colorectal cancer.

Methods
=======

The English language medical literature was searched for relevant articles related to the use of panitumumab in metastatic colorectal cancer. The search terms used were "Panitumumab or ABX-EGF," "colorectal cancer" and the articles published covered a period between 1988 to November 2006. The following databases were used: PubMed, <http://www.ncbi.nlm.nih.gov/entrez>National Cancer Institute, <http://www.cancer.gov>Clinical Evidence (BMJ), <http://www.clinicalevidence.com>Clinical Trials, <http://www.clinicaltrials.com>

The annual scientific sessions from the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), American Association of Cancer Research (AACR), and ASCO Gastrointestinal Cancers Symposium (ASCO GI) were searched for relevant meeting abstracts. A total of 19 articles were identified, 11 of those represented by systematic review. Nine articles were excluded because they were considered not relevant ([Table 1](#t1-ce-2-081){ref-type="table"}). A further paper was identified ([@b34-ce-2-081]) replacing two earlier abstracts.

Few studies were identified for panitumumab use specifically in colorectal cancer; this indication was however investigated in early trials in which the drug was used in a variety of solid tumors. No health economics publications were found.

Disease overview
================

Colorectal cancer is one of the most common malignancies. The worldwide incidence estimated in 2002 was 1 023 152 (550 465 men, 472 687 women) ([@b18-ce-2-081]). Of newly diagnosed patients, 40% have metastatic disease at diagnosis, and approximately 25% of patients with localized disease at diagnosis will ultimately develop metastatic disease. With the exception of patients with localized liver metastases, which is potentially curable by surgical treatment, the majority of patients with metastatic colorectal cancer die of their disease.

The essential element of the etiology of colorectal cancer is a process of genetic change in the epithelial cells of the colonic mucosa ([@b35-ce-2-081]). Epidemiologic factors have provided initial evidence about specific factors that initiate the process of carcinogenesis in large bowel mucosa ([@b37-ce-2-081]). Chief among the factors that can initiate colorectal cancer development are a predisposition to mutagen effects, fecal mutagens, meat intake, bile acids, altered vitamin and mineral intake, and fecal pH. Investigators are most suspicious of the role of diet in causation of colorectal cancer ([@b25-ce-2-081]).

The incidence of the disease has been slowly declining over the past few decades, probably because of improved screening and earlier detection of premalignant disease. Colorectal cancer lends itself to screening because of the long period between the development of early mucosal abnormalities and the development of invasive carcinoma. Adenomatous polyps are the well-described precursor lesions of invasive colorectal cancer and can be effectively managed by endoscopic intervention. In the general population, the risk of development of a colorectal adenoma is approximately 19%, and it is estimated that 2--5% of these sporadic polyps will develop into an invasive carcinoma ([@b26-ce-2-081]). Unfortunately, adherence to screening recommendations by individuals at average risk is suboptimal, and despite the ability to prevent colorectal cancer this disease remains a major cause of morbidity and mortality in western society.

Current therapy options
=======================

The treatment options for colorectal cancer depend on disease stage at diagnosis. In locally advanced disease (stage I, II, III) surgery is the most effective intervention. Even in cases of metastatic colorectal carcinoma, surgery may be required for palliation. The benefits of systemic chemotherapy in the treatment of metastatic colorectal cancer have become established in the past 20 years, and there is good evidence of improved quality of life and OS ([@b31-ce-2-081]).

Fluorouracil has been considered the standard of care in the past decade used both in advanced and in metastatic disease. It has been used with and without biomodulating agents such as leucovorin and methotrexate, alone as an intravenous bolus, by high-dose weekly 24-hour infusions, or by protracted continuous infusions which offer a higher response rate (33% vs 14%, *P*=0.0004) ([@b8-ce-2-081]). However, progression-free survival (PFS) differs only modestly, being 5 weeks longer with continuous infusion (*P*=0.001) and there is no statistical benefit in terms of OS ([@b8-ce-2-081]).

Capecitabine provides an oral alternative to intravenous fluorouracil in both the metastatic and adjuvant setting. In two separate phase III trials, capecitabine has demonstrated superior response rate, equivalent PFS and OS, and decreased toxicity compared with bolus fluorouracil/leucovorin ([@b16-ce-2-081]; [@b33-ce-2-081]).

The modern era of colorectal cancer chemotherapy began in the mid-1990s when two novel chemotherapeutic agents---irinotecan and oxaliplatin---were found to have significant activity in metastatic colorectal cancer. The introduction of irinotecan and oxaliplatin has nearly doubled the median survival of patients with metastatic disease, replacing fluorouracil/folinic acid as the standard of care. The consequence of the combination regimens using irinotecan ([@b27-ce-2-081]) oxaliplatin ([@b9-ce-2-081]) and fluorouracil/folinic acid has been to increase the efficacy of first-line therapy from response rates of about 20%, a time to progression of 4 months and a median OS of approximately 10 months in 1995, to response rates of between 35% and \>50%, a median time to progression in the region of 8 months, and median OS of up to 21.5 months in 2004 ([@b32-ce-2-081]). Although the combination of oxaliplatin/fluorouracil/folinic acid (FOLFOX) demonstrated significantly higher efficacy compared with irinotecan/fluorouracil bolus/leucovorin (IFL), oxaliplatin/folinic acid (FOLOX) and irinotecan/fluorouracil bolus + continuous infusion leucovorin (FOLFIRI) appear to be equivalent in terms of efficacy. A phase III trial comparing FOLFIRI and FOLFOX6 (oxaliplatin/fluorouracil/folinic acid) with crossover at progression, found that response rate (56% vs 54%), PFS (8.5 vs 8.1 months), and OS (21.5 vs 20.6 months) were nearly identical ([@b32-ce-2-081]).

Recently, targeted therapy has presented the opportunity to improve on the efficacy of current treatments without exacerbating the associated toxicity; the advent of monoclonal antibodies has added improvements in survival and costs in metastatic colorectal cancer. Attention has focused on EGFR and on vascular endothelial growth factor (VEGF), which is implicated in angiogenesis.

Angiogenesis is the process of new blood vessel formation and it is considered critical for tumor growth. Unlike traditional chemotherapy, angiogenesis inhibitors specifically target the formation of new blood vessels without interfering with dividing hematopoietic stem cells or gastrointestinal cells. At the time of writing, bevacizumab (Avastin^®^), a humanized antibody directed against VEGF, has been approved in the USA and in Europe for first-line therapy in metastatic colorectal cancer. Approval was based on a phase III pivotal trial that evaluated the activity of bevacizumab 5 mg/kg every 2 weeks when added to IFL, the standard care in the USA. Significant differences in PFS (10.6 vs 6.2 months) and OS (20.6 vs 15.6 months) were registered in the bevacizumab-containing arm. Improvement in response rate (45% vs 35%) was moderate, maybe because the angiogenesis inhibitors mainly result in tumor growth inhibition rather than regression ([@b17-ce-2-081]). The Eastern Cooperative Oncology Group (ECOG) trial E3200 has evaluated the activity of bevacizumab in combination with oxaliplatin and fluorouracil as second-line therapy. The final results, presented at the ASCO meeting 2005, showed an advantage (12.5 vs 10.7 months) in terms of OS, with a reduced hazard ratio for death of 0.73 ([@b11-ce-2-081]).

Another potential target in colorectal cancer treatment is EGFR, a cell membrane growth factor receptor with tyrosine kinase activity which plays a crucial role in the control of key cellular transduction pathways in both normal and cancer cells. The EGFR is overexpressed in a variety of human tumors, including colorectal, head and neck, breast, lung, prostate, kidney, pancreas, ovary, brain, and bladder cancers ([@b38-ce-2-081]; [@b21-ce-2-081]). Functional activation of EGFR is due to the formation of either EGFR-EGFR homodimers or of heterodimers with one of the other three members of the EGFR family of growth factor receptors (HER-2, HER-3, and HER-4) following binding of an EGFR-selective ligand, such as EGF, transforming growth factor alfa (TGF-alfa), or amphiregulin. This results in conformational changes that allow activation of the EGFR tyrosine kinase with the phosphorylation of specific tyrosine residues within the EGFR intracellular carboxyl-terminal domain. Phosphorylated tyrosine residues serve as docking sites for several signaling proteins that initiate a complex intracellular signal transduction cascade that ultimately affects regulation of gene transcription ([@b39-ce-2-081]; [@b39-ce-2-081]). The activity of EGFR could be neutralized by monoclonal antibodies that bind to the extracellular domain and competitively inhibit ligand binding to prevent receptor dimerization and subsequent activation of the receptor tyrosine kinase. The EGFR-monoclonal antibody complex is internalized, causing a transient decrease in EGFR expression ([@b6-ce-2-081]). Eighty percent of colorectal cancers are EGFR-positive by immunohistochemistry staining ([@b7-ce-2-081]). This parameter does not correlate with clinical response and, moreover, even EGFR immunohistochemistry-negative tumors could respond to EGFR inhibitor treatment ([@b5-ce-2-081]).

Cetuximab (Erbitux^®^) is a chimeric human monoclonal antibody against EGFR, approved worldwide in metastatic colorectal cancer refractory to irinotecan-based therapy. Cetuximab is typically administered at 400 mg/m^2^ initially, followed by 250 mg/m^2^ weekly thereafter. The first phase II nonrandomized trials attested to its activity as monotherapy (response rate 11%, stable disease 35%) and in combination with IFL (response rate 19%, stable disease 27%) in patients who had failed prior irinotecan therapy ([@b28-ce-2-081], [@b29-ce-2-081]). These results were confirmed in a large, randomized, phase III trial carried out in 329 patients, of whom 218 received cetuximab plus irinotecan and 111 cetuximab alone ([@b7-ce-2-081]). The response rate with the combination was significantly higher than with monotherapy (23% vs 11%, *P*=0.007). Disease control rates were 56% and 32%, respectively, and time to progression was also significantly greater for the combination arm (4.1 vs 1.5 months, *P*\<0.001). The median survival time was 8.6 months in the cetuximab arm (*P*=0.48).

The role of cetuximab combined with FOLFOX4 (oxaliplatin/fluorouracil/leucovorin) in a first-line setting has been tested in a phase II trial of 43 patients. A total of 9% of patients achieved a complete remission and 63% had partial response, with an overall confirmed response rate of 72%. Ten patients underwent liver metastasectomy, the overall response rate was 81%, and the PFS was 10.2 months ([@b10-ce-2-081]). More information about the role of EGFR inhibition as a first-line option in colorectal cancer should come from the Crystal study, a large multicenter study in which 1212 patients with previously untreated metastatic colorectal cancer expressing EGFR have been randomized to receive FOLFIRI with or without cetuximab; preliminary data are expected in 2007.

These interesting results have led to investigation of the combination between EGFR inhibitors and antiangiogenic agents. The preliminary results of a randomized phase II study in patients with irinotecan-refractory, metastatic colorectal cancer have been reported. In this trial, named the BOND-2 study, 39 patients were treated with the combination of cetuximab, irinotecan, and bevacizumab, and 35 patients received cetuximab plus bevacizumab treatment. The authors have reported a 37% response rate with a time to progression of 7.9 months in the triple-drug combination, compared with 20% and 5.6 months in patients treated with cetuximab plus bevacizumab ([@b30-ce-2-081]).

Targeted therapy represents a new frontier in treatment of colorectal cancer. New compounds such as panitumumab could have the same efficacy as cetuximab with lower incidence of hypersensitivity reactions due to it being a fully human antibody.

Outcomes achieved in clinical development
=========================================

Panitumumab is being evaluated in clinical trials as both a monotherapy and in combination with other agents for the treatment of various types of cancer including colorectal, lung, and kidney.

Several phase II studies with panitumumab have been carried out, and other phase III trials are ongoing. An important difference compared with cetuximab is that panitumumab is a fully human Ig2 monoclonal antibody created by Abgenix's XenoMouse technology, which creates antibodies that contain no murine protein ([@b22-ce-2-081]). The goal of this technique is to offer effective high-affinity therapy with a minimum of allergic reactions or anaphylaxis.

Monotherapy
-----------

Until now, 1130 patients have been treated with panitumumab as monotherapy, including 789 with metastatic colorectal cancer, 229 of whom have been enrolled in a phase III trial. The remaining 341 patients had renal cell carcinoma and other solid tumors.

The phase I data of safety, pharmacokinetics, and antitumor activity in solid tumors were presented at the ASCO meeting 2005 ([@b36-ce-2-081]). In this study sequential cohorts of patients were enrolled to receive four infusions at different dose levels and schedules of panitumumab monotherapy ranging from 0.01 to 5 mg/kg once per week, to 6 mg/kg once every 2 weeks, or 9 mg/kg once every 3 weeks. Patients were prescreened for EGFR expression by immunohistochemistry and had to have at least 1+ (defined as low staining intensity) expression in ≥10% of tumor cells. A total of 96 patients were enrolled; tumor types included 39 colorectal, 21 prostate, 15 renal, 14 nonsmall cell lung (NSCLC), three pancreatic, three esophageal/gastroesophageal, and one anal cancer. Pharmacokinetic exposure was similar between 2.5 mg/kg per week, 6 mg/kg every 2 weeks, and 9 mg/kg every 3 weeks.

By investigator assessment, five patients had a partial response, all of whom had colon cancer and 19 had stable disease including eight with colorectal cancer, five with NSCLC, three with prostate cancer, two with renal cancer, and one with gastroesophageal cancer. The incidence of skin-related toxicities was dose dependent and reached a plateau at \>2.0 mg/kg once per week. Grade 3 or 4 related adverse events were noted in 10% of patients with grade 3 skin-related effects being the most frequent (7% of patients). No maximum tolerated dose was reached, and no human antihuman antibody formation or infusion-related reactions was observed.

A phase II open-label trial presented at the ASCO meeting 2004 ([@b12-ce-2-081]; [@b20-ce-2-081]) assessed the efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer who failed therapy with a fluoropyrimidine, fluorouracil (± leucovorin), and either irinotecan or oxaliplatin. A total of 150 patients were enrolled and received at least one dose of panitumumab; 148 were included in the safety and efficacy analysis. Patients were subdivided into two cohorts according to immunohistochemistry tumor staining. Cohort A included patients with EGFR 2+ (defined as moderate staining intensity by immunohistochemistry) or 3+ (defined as high staining intensity immunohistochemistry) in ≥10% tumor cells; cohort B included patients with EGFR of the sum of 1+, 2+, and 3+ in ≥10% of tumor cells, but with the sum of 2+ and 3+ in \<10% of tumor cells. Panitumumab was given intravenously at 2.5 mg/kg once weekly in 8-week cycles; patients continued treatment until disease progression or unacceptable toxicity. Panitumumab monotherapy resulted in a 10% response rate with stable disease in 38% of patients; the median duration of response was 5.2 months \[95% confidence interval (CI) 4.5, 7.5 months\]. The median PFS was 2 months (95% CI 1.9, 3.8 months), and the median survival amounted to 7.9 months (95% CI 5.7, 9.9 months). The four most frequently reported grade 3 or 4 treatment-related adverse effects were rash, fatigue, vomiting, nausea, and pruritus. Skin-related adverse events were reported in 141 patients (95%; 5% grade 3 and no grade 4). One infusion-related grade 3 adverse event was registered but no dose modification was required. No human antihuman antibodies were observed. A relationship between skin rash severity and survival seems to be similar to that noted with the use of cetuximab ([@b14-ce-2-081]). Moreover, its efficacy appears to be similar in patients with both low and negative EGFR levels ([@b13-ce-2-081], [@b15-ce-2-081]).

This has been confirmed by a multicenter, single-arm, phase II study that enrolled patients with low (defined as 1--9% of tumor membrane staining by immunohistochemistry) or negative (\<1% tumor membrane staining) EGFR levels. Patients had failed 2--3 prior regimens containing an adequate dose of fluoropyrimidine, irinotecan, and oxaliplatin; they received panitumumab at the dose of 6 mg/kg every 2 weeks. Tumor assessments were taken from week 8 until disease progression and were performed by an independent eligibility review committee. The interim analysis included 89 patients, 57% of whom were male, and with a median age of 61 years. Six of thirty-five (2%) partial responses were reported in patients with low expression of EGFR (\<1%) and 4/51 (8%) in patients with negative levels of EGFR, and stable disease occurred in 11/35 (31%) versus 15/51 (29%), with a disease control rate of 37% versus 39%. Time to progression was 9 weeks for both low or negative EGFR patients, with duration of response of 31 versus 20 weeks, and PFS of 7 versus 8 weeks. The most common adverse events were dermatitis acneiform (72% in total, 6% grade 3/4), erythema (69%, 6%), pruritus (65%, 4%), and hypomagnesemia (53%, 10%). Three patients (\<3%) had an infusion reaction per investigator (one grade 3 infusion reaction). The overall response rate was judged the same in the local and in the central review committee ([@b15-ce-2-081]).

The activity of panitumumab has also been tested in patients with metastatic colorectal cancer expressing ≥10% EGFR. Patients with documented disease progression during or following adequate doses of fluoropyrimidine, irinotecan, and oxaliplatin regimens received panitumumab 6 mg/kg every 2 weeks until disease progression. Study endpoint was objective response rate (ORR) at week 16. In the interim analysis, 91 enrolled patients received more than one dose of panitumumab. The efficacy set consisted of 23 male and 16 female patients, median age 58.6, 95% ECOG score ≤1, 74% with colon cancer, and 26% with rectal cancer. At week 16, three patients (8%) had a partial response, eight (21%) had stable disease, and 19 (49%) had disease progression. Response durations were 12.4, 13.2, and 14.0 weeks. As main adverse events skin toxicity was reported in 96% of the cases, 8% for nail and 5% for eye toxicity, 27% for diarrhea, and 12% for hypomagnesemia. One patient had a grade 3 hypersensitivity reaction related to panitumumab ([@b3-ce-2-081]).

A large, phase III, multicenter, pivotal trial (study 408) has randomized patients with oxaliplatin and irinotecan-refractory EGFR-expressing metastatic colorectal cancer between best supportive care (BSC) and BSC plus panitumumab at a dose of 6 mg/m^2^ every 2 weeks ([@b34-ce-2-081]). The aim of this pivotal trial was to show a significant difference in PFS. A total of 1040 patients were screened, of whom only 463 were randomized (1:1); 231 received panitumumab with BSC, 232 received BSC only, 174 patients received panitumumab under crossover protocol. Patients were stratified for sex, age, ECOG performance status, number of metastatic sites, prior chemotherapy, and intensity of EGFR staining. Panitumumab showed a 46% decrease in tumor progression rate versus BSC alone (hazard ratio 0.54; 95% CI 0.44, 0.66; *P*\<0.000000001, stratified log-rank test). The subset analyses demonstrated consistent treatment effect of panitumumab in all subgroups of patients. The response rate was significantly higher in the panitumumab arm, with 8% partial response rate and 28% achieving stable disease, compared with no partial responses and 10% stable disease with BSC alone. The time to response was 8 weeks, and the median duration of the response was 17 weeks. Panitumumab also showed activity in crossover study patients with 10% achieving partial response and 32% stable disease.

Skin reactions of any grade occurred in 90% of patients receiving panitumumab, and in 9% of those receiving BSC; the incidence of grade 3--4 skin-related adverse reactions was 14% and 0% for panitumumab and BSC, respectively. Skin reactions consisted of dermatitis acneiform 7%, erythema 5%, pruritus 2%, and rash 1%.

Overall, 33% of patients in the panitumumab arm experienced grade 3 adverse effects, mainly due to abdominal pain (23% vs 17% with BSC alone), fatigue (24% vs 15%), nausea (22% vs 15%), diarrhea (21% vs 11%), and 2% of all patients experienced grade 4 toxicity. Hypomagnesemia occurred in 38% of patients treated with panitumumab versus 2% of those in the BSC arm; the patients with grade 3--4 toxicity (3% in both groups) received intravenous magnesium. The incidence of potential infusion reactions was low with no grade 3--4 reactions. Only one grade 2 hypersensitivity reaction was reported and treatment was discontinued ([@b34-ce-2-081]).

Recently, data have been presented from the exploratory efficacy analyses from this trial of PFS, ORR, and OS in patient subsets based on baseline performance status (ECOG score 0--1 vs 2--3) and age (\<65 vs ≥65 years). Most had ECOG score of 0--1 (87% panitumumab, 84% BSC); 42% of panitumumab patients and 39% of the BSC group were aged ≥65 years. The treatment effect on PFS favored panitumumab regardless of age or ECOG status. Among the panitumumab patients, similar PFS, OS, and ORR were seen between elderly and younger patients and within both ECOG status groups ([@b34-ce-2-081]).

Combination therapy
-------------------

There are also data showing good activity as first-line treatment of metastatic colorectal cancer when panitumumab 2.5 mg/kg once weekly is combined with chemotherapy. These data are from a two-part phase II study, in the first part of which panitumumab is added to IFL.

Of 19 patients, 47% had a response (complete or partial) and disease was stable in 26%, with a median PFS of 5.6 months and median OS of 16.8 months ([@b2-ce-2-081]). The rate of early disease progression was slow and was experienced in only one patient; all patients who responded to the panitumumab combination developed skin rash. The second part of this study enrolled patients with the same characteristics (n=24) but they received panitumumab with FOLFIRI as first-line chemotherapy. The primary endpoint of the study was the incidence of diarrhea; the secondary endpoints included ORR, PFS, and OS. Thirty-three percent of patients achieved partial response and 46% had stable disease, with a PFS of 10.9 months. The median OS was not reached because at the time of analysis (May 2005) 23 of 24 patients were still alive ([@b14-ce-2-081]). The incidence of grade 3 and 4 diarrhea was 53% and 5%, respectively, for part 1 of the study, and 25% and 0%, respectively, in part 2. Treatment-related skin reactions were present in both parts, reaching grade 3 severity in 16% of patients in part 1 and in 17% of patients in part 2; there were no grade 4 reactions. Other grade 3 treatment-related adverse events included hypokalemia (16%), fatigue (11%), and nausea (5%) in part 1; none of these events occurred in part 2. Grade 4 treatment-related hypomagnesemia occurred in one patient in each part of the study. There were no severe infusion reactions, or human antihuman antibody formation ([@b2-ce-2-081]; [@b14-ce-2-081]).

The activity of panitumumab in combination with FOLFIRI and AMG706 was tested by [@b4-ce-2-081]. AMG706 is an oral, multikinase inhibitor with antiangiogenic activity that selectively targets VEGF, PDGF (platelet-derived growth factor), and Kit receptors. In this ongoing phase I study panitumumab was given at a dosage of 6 mg/kg by intravenous infusion every 2 weeks, and AMG706 was given continuously from day 3 of cycle 1 in escalating doses; patients also received either FOLFOX or FOLFIRI based on prior systemic therapy. Dose-limiting toxicity was assessed during the first two cycles, and tumor response was evaluated every 6--8 weeks from week 6. At the time of writing, data are available only for the cohort containing FOLFIRI. Twenty-two patients were enrolled and had received at least one dose of AMG706 at the time of data cut-off (50 mg, n=12; 75 mg, n=7; 100 mg, n=3), including 11 men and 11 women, with median age of 53 years. There were two dose-limiting toxicities of AMG706, represented by diarrhea (50 mg) and deep vein thrombosis (75 mg). These preliminary data show that coadministration of FOLFIRI, panitumumab, and AMG706 is safe, with little effect on the pharmacokinetics of AMG706 at a dose of 50 mg ([@b4-ce-2-081]).

Ongoing studies
===============

Several studies are ongoing in metastatic colorectal cancer utilizing panitumumab in combination with other chemotherapeutic agents or with targeted therapy in first-, second-, and third-line treatment. One of the largest is PACCE (Panitumumab Advanced Colorectal Cancer Evaluation), which is a multicenter trial in the US in which more than 1000 patients were randomized for first-line treatment of metastatic colorectal cancer with chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab ± panitumumab; recruitment was initiated in 2005 and was concluded in September 2006. The preliminary analysis showed a statistically significant difference in favor of the control arm, with an increase in toxicity in the panitumumab-containing arm ([@b1-ce-2-081]).

Patient group/population
========================

Panitumumab is approved in the US for the treatment of patients with EGFR-positive metastatic colorectal cancer with disease progression on, or following, fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The drug is not approved in the EU.

Panitumumab is a fully human monoclonal antibody that targets the extracellular domains of EGFR. To date in all trials with panitumumab EGFR immunohistochemistry expression was assessed. Response to treatment was seen in patients with metastatic colorectal cancer with both low and negative EGFR levels ([@b13-ce-2-081], [@b15-ce-2-081]). This retrospective analysis confirmed that skin rash could correlate with clinical response but not with survival. However, despite this finding, regulatory authorities have not reached a decision that could restrict continued dosing with panitumumab in patients who do not experience skin rash. Rash associated with panitumumab is common and can be classified according to the clinical dermatological manifestations, requiring specific treatment strategies ([@b24-ce-2-081]).

Clinical potential
==================

Within the last few years the natural history of metastatic colorectal cancer treatment has changed, with a dramatic improvement in OS especially with the combined modality therapy of conventional chemotherapy plus biologic agents that target a specific protein involved in tumor growth. Panitumumab has shown clear activity in metastatic colorectal cancer as a single agent and in combination chemotherapy. Panitumumab is well tolerated, with the main toxicity being skin reactions, although grade 4 severity has not been observed; no maximum tolerated dose has been reported. Because it is a fully human antibody, infusion-related reactions have been minimal; only 1/148 patients experienced a grade 3 reaction and 1/463 patients discontinued treatment due to grade 2 hypersensitivity reaction in clinical trials conducted to date. Another potential advantage of panitumumab lies in its relative ease of use, with pharmacokinetic parameters unaffected by administration every week, or every 2 or 3 weeks.

Encouraging results from trials reported so far demonstrate a potential therapeutic value of this agent, but the data need to be confirmed in large multicenter trials that explore the role of panitumumab as a first- as well as a second-line option in colorectal cancer.
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Evidence base included in the review

  **Category**                    **Number of records**   
  ------------------------------- ----------------------- ----
  Initial search                  19                      11
    records excluded              9                       3
    records included              10                      8
  Additional studies identified   1                       0
  Level 1 clinical evidence       0                       2
  Level 2 clinical evidence       2                       5
  Level ≥3 clinical evidence      9                       1
    trials other than RCT         0                       0
    case reports                  0                       0
  Economic evidence               0                       0

For definition of levels of evidence, see Editorial Information on inside back cover.

RCT, randomized controlled trial.
